{
    "clinical_study": {
        "@rank": "93972", 
        "arm_group": {
            "arm_group_label": "adalimumab", 
            "arm_group_type": "Experimental", 
            "description": "concentration 40mg/0.4 mL"
        }, 
        "brief_summary": {
            "textblock": "Phase 2b,open label, multicenter study in rheumatoid arthritis for subjects who completed\n      the previous M13-390 study."
        }, 
        "brief_title": "Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has completed the preceding Study M13-390 for rheumatoid arthritis and has\n             not developed any discontinuation criteria from that study.\n\n          2. If female, subject is either not of childbearing potential, defined as postmenopausal\n             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral\n             oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing\n             an approved method of birth control throughout the study and for 150 days after last\n             dose of study drug.  Examples of approved methods of birth control include the\n             following (see local informed consent for more detail):\n\n               -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD);\n\n               -  Hormonal contraceptives for 90 days prior to study drug administration;\n\n               -  A vasectomized partner;\n\n          3. Subjects must be able and willing to self-administer subcutaneous (SC) injections or\n             have a qualified person available to administer SC injections.\n\n          4. Subject is judged to be in good general health as determined by the Principal\n             Investigator based upon the results of medical history, physical examination,\n             laboratory profile performed at Baseline.\n\n          5. Subjects must be able and willing to provide written informed consent and to comply\n             with the requirements of this study protocol.\n\n        Exclusion Criteria:\n\n          1. Ongoing infections at Week 0 that have NOT been successfully treated.  Subjects with\n             ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the\n             infection has been successfully treated.\n\n          2. Subject currently uses or plans to use anti-retroviral therapy at any time during the\n             study.\n\n          3. Subject plans to use any live vaccine during the study.\n\n          4. Positive pregnancy test at Baseline (Week 0).\n\n          5. Subject is considered by the investigator, for any reason, to be an unsuitable\n             candidate for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752855", 
            "org_study_id": "M13-692", 
            "secondary_id": "2012-003881-42"
        }, 
        "intervention": {
            "arm_group_label": "adalimumab", 
            "description": "concentration 40mg/0.4mL", 
            "intervention_name": "adalimumab", 
            "intervention_type": "Biological", 
            "other_name": "Humira"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Rheumatoid Arthritis", 
        "lastchanged_date": "November 4, 2013", 
        "link": {
            "description": "This clinical study may be evaluating a usage that is not currently FDA-approved. Please see US Prescribing Information for approved uses.", 
            "url": "http://rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mesa", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85202"
                    }, 
                    "name": "Site Reference ID/Investigator# 92113"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hemet", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92543"
                    }, 
                    "name": "Site Reference ID/Investigator# 92118"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67203"
                    }, 
                    "name": "Site Reference ID/Investigator# 92117"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clifton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07012"
                    }, 
                    "name": "Site Reference ID/Investigator# 92115"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19152"
                    }, 
                    "name": "Site Reference ID/Investigator# 92116"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29406"
                    }, 
                    "name": "Site Reference ID/Investigator# 92114"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Site Reference ID/Investigator# 92053"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Site Reference ID/Investigator# 92054"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "638 00"
                    }, 
                    "name": "Site Reference ID/Investigator# 91954"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague 2", 
                        "country": "Czech Republic", 
                        "zip": "128 50"
                    }, 
                    "name": "Site Reference ID/Investigator# 91955"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uherske Hradiste", 
                        "country": "Czech Republic", 
                        "zip": "686 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 91953"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zlin", 
                        "country": "Czech Republic", 
                        "zip": "760 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 91956"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ratingen", 
                        "country": "Germany", 
                        "zip": "40882"
                    }, 
                    "name": "Site Reference ID/Investigator# 92073"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vega Baja", 
                        "country": "Puerto Rico", 
                        "zip": "00693"
                    }, 
                    "name": "Site Reference ID/Investigator# 92074"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania", 
                        "zip": "020475"
                    }, 
                    "name": "Site Reference ID/Investigator# 92093"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cluj-Napoca", 
                        "country": "Romania", 
                        "zip": "400006"
                    }, 
                    "name": "Site Reference ID/Investigator# 92095"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ploiesti", 
                        "country": "Romania", 
                        "zip": "100337"
                    }, 
                    "name": "Site Reference ID/Investigator# 92094"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Banska Bystrica", 
                        "country": "Slovakia", 
                        "zip": "97405"
                    }, 
                    "name": "Site Reference ID/Investigator# 92096"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Senica", 
                        "country": "Slovakia", 
                        "zip": "905 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 92097"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zilina", 
                        "country": "Slovakia", 
                        "zip": "010 01"
                    }, 
                    "name": "Site Reference ID/Investigator# 92098"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Czech Republic", 
                "Germany", 
                "Puerto Rico", 
                "Romania", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects Who Completed Preceding Study M13-390 With Adalimumab", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Uday  Arulmani, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in disease activity score (DAS28) [CRP] with baseline being Study M13-390 Week 0 Visit.", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and Week 24"
            }, 
            {
                "measure": "Response defined by American College of Rheumatology (ACR) 20/50/70/90/100 criteria with baseline being Study M13-390 Week 0 Visit.", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and Week 24"
            }, 
            {
                "measure": "Change from baseline in Health assessment Questionnaire (HAQ-DI) with baseline being Study M13-390 Week 0 Visit.", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}